N. Rueda

发表

Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome

R. Vidal, Maria-Clemencia Hernández, C. Martínez-Cué, 2018, Molecular Neurobiology.

Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model for Down syndrome

C. Martínez-Cué, J. Flórez, N. Rueda, 2006, Genes, brain, and behavior.

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

C. Alonso-González, Alicia González, C. Martínez-Campa, 2020, Scientific Reports.

Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies

M. Berciano, C. Martínez-Cué, M. Lafarga, 2021, International journal of molecular sciences.

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice.

R. Bartesaghi, A. Velasco, C. Martínez-Cué, 2020, The Journal of nutrition.

Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.

E. Valdizán, C. Martínez-Cué, M. Llorens-Martín, 2010, Journal of Alzheimer's disease : JAD.

Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome

E. B. Parisotto, C. Martínez-Cué, E. Sánchez-Barceló, 2016, Neurochemical Research.

The Ts65Dn mouse model of Down syndrome shows reduced expression of the Bcl-XL antiapoptotic protein in the hippocampus not accompanied by changes in molecular or cellular markers of cell death

C. Martínez-Cué, J. Flórez, N. Rueda, 2011, International Journal of Developmental Neuroscience.

Apoptosis in Down’s syndrome: lessons from studies of human and mouse models

C. Martínez-Cué, J. Flórez, N. Rueda, 2013, Apoptosis.

Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease

C. Martínez-Cué, J. Riancho, V. Vidal, 2021, Frontiers in Pharmacology.

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

E. B. Parisotto, C. Martínez-Cué, D. W. Filho, 2017, Behavioural Brain Research.

Title: Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

E. B. Parisotto, D. W. Filho, E. Sánchez-Barceló, 2017 .

Long‐term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle‐aged Ts65Dn mice, a model of Down syndrome

C. Martínez-Cué, E. Sánchez-Barceló, J. Flórez, 2013, Journal of pineal research.

Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome

R. Vidal, C. Martínez-Cué, E. Sánchez-Barceló, 2014, Journal of pineal research.

Cellular Senescence in Neurodegenerative Diseases

C. Martínez-Cué, N. Rueda, 2020, Frontiers in Cellular Neuroscience.

Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease

C. Martínez-Cué, V. Vidal, P. Martínez, 2014, Neuroscience.

Reducing GABAA α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome

M. Honer, R. Vidal, Á. Pazos, 2013, The Journal of Neuroscience.

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

M. Berciano, C. Martínez-Cué, M. Lafarga, 2022, Antioxidants.

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

C. Martínez-Cué, J. Flórez, N. Rueda, 2012, Neural plasticity.

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

C. Martínez-Cué, V. Vidal, Susana García-Cerro, 2017, Neurobiology of Disease.

Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.

R. Reiter, C. Martínez-Cué, E. Sánchez-Barceló, 2017, Current medicinal chemistry.

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

C. Martínez-Cué, N. Rueda, 2020, International journal of molecular sciences.

Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

C. Martínez-Cué, J. Merino, M. Llorens-Martín, 2018, Brain, Behavior, and Immunity.

The GABAAα5-selective Modulator, RO4938581, Rescues Protein Anomalies in the Ts65Dn Mouse Model of Down Syndrome

K. Gardiner, C. Martínez-Cué, N. Rueda, 2017, Neuroscience.

Effects of voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a model of Down syndrome

G. Tejeda, C. Martínez-Cué, M. Llorens-Martín, 2010, Neuroscience.

Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome

C. Martínez-Cué, J. Flórez, N. Rueda, 2008, Behavioural Brain Research.

Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome

M. Davisson, C. Martínez-Cué, J. Flórez, 2005, Behavioural Brain Research.

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

Pedro Ramos-Cabrer, M. Berciano, C. Martínez-Cué, 2018, Neurobiology of Disease.

Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process

C. Alonso-González, Alicia González, C. Martínez-Campa, 2019, Front. Physiol..

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.

M. Dierssen, C. Martínez-Cué, J. Flórez, 2020, Progress in brain research.

Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome

R. Vidal, C. Martínez-Cué, M. Arbonés, 2014, PloS one.

receptors partially improves cognitive , electrophysiological and morphological hippocampal defects in the Ts 65 Dn model of Down syndrome

R. Vidal, C. Martínez-Cué, L. Ozmen, 2018 .

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

C. Alonso-González, Alicia González, C. Martínez-Campa, 2020, Scientific Reports.

Breast cancer therapy based on melatonin.

C. Alonso-González, E. Sánchez-Barceló, M. D. Mediavilla, 2012, Recent patents on endocrine, metabolic & immune drug discovery.

Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome

C. Martínez-Cué, A. Sharma, V. Vidal, 2012, Neuroscience.

Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome

R. Mostany, Á. Pazos, C. Martínez-Cué, 2005, Neuroscience Letters.

Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome

R. Bartesaghi, C. Martínez-Cué, V. Vidal, 2020, Nutritional neuroscience.

Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice.

R. Bartesaghi, C. Martínez-Cué, V. Vidal, 2020, The Journal of nutrition.

Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome

C. Martínez-Cué, J. Flórez, N. Rueda, 2008, Neuroscience Letters.

Both increases in immature dentate neuron number and decreases of immobility time in the forced swim test occurred in parallel after environmental enrichment of mice

C. Martínez-Cué, M. Llorens-Martín, J. Flórez, 2007, Neuroscience.

Common Pathogenic Mechanisms between Down Syndrome and Alzheimer's Disease: Steps toward Therapy

A. Granholm, F. Schmitt, D. Colas, 2018 .